Sovargen dosed the first patient in a Phase 1b trial of paxalisib for rare seizure disorders, triggering a $2 million development milestone payment to Kazia Therapeutics. The event expands paxalisib development beyond oncology and gives Kazia eligibility for up to $17 million in further development and regulatory milestones.

Key Highlights

  • Focal cortical dysplasia type 2 currently has no approved therapies.
  • Paxalisib development is expanding beyond oncology into intractable epilepsy associated with focal cortical dysplasia and tuberous sclerosis complex.
  • Kazia and Sovargen entered an exclusive licensing agreement in March 2024 covering paxalisib development, Manufacturing and commercialization for mTORopathy-related epilepsies.
  • Kazia can receive up to $17 million in further development and regulatory milestone payments, plus sub-licensing Revenue and royalties on net sales.

The milestone extends paxalisib development beyond oncology into intractable epilepsy associated with focal cortical dysplasia and tuberous sclerosis complex.

Paxalisib License Sets Milestone Terms

Kazia (NASDAQ: KZIA) and Sovargen entered their exclusive licensing agreement in March 2024. The arrangement covers paxalisib development, manufacturing and commercialization for mTORopathy-related epilepsies. Kazia can receive further development and regulatory milestone payments of up to $17 million, along with a percentage of sub-licensing revenue and royalties on net sales of products incorporating paxalisib. The clinical study is evaluating paxalisib in patients with treatment-resistant seizures linked to the two rare neurological disorders. Paxalisib is being developed by Sovargen under the license granted by Kazia.

Clinical Program Moves Beyond Oncology

The first-patient dosing marks a development milestone for Kazia’s non-oncology program. Kazia said its own clinical focus for paxalisib remains oncology while Sovargen advances the seizure-disorder study. Sovargen said enrollment is continuing, with the trial intended to generate data on paxalisib’s potential in these neurological indications.